Firm Welcomes Nationally Recognized Public Servant and Iraq War Veteran

Milwaukee – LAWFUEL – The Law Newswire – Foley & Lardner LLP announced today that former Wisconsin Public Service Commissioner and Iraq War veteran Robert “Bert” Garvin joined the firm as of counsel in the Litigation Department and Energy Regulation Practice.

“We are delighted to have Bert join us. His demonstrated leadership and extensive knowledge of national and regional energy policy issues, such as regional electric markets and global climate change, will have significant impact on our Midwest and national clients,” said Ralf Boer, the firm’s chairman and CEO. “Bert is a talented lawyer who brings to our practice and our clients valuable experience in regulatory, legislative and policy matters in these critical areas.”

Garvin previously served as a member of the three-person Public Service Commission of Wisconsin from March 2001 to February 2007. The Commission is the agency that regulates the state’s energy, telecommunications and water utilities.

At Foley, Garvin will counsel clients throughout the country on issues related to electric transmission policy, regional electric generation and capacity markets, energy efficiency, renewable energy and the energy industry’s response to global climate change.Garvin was the primary author for many of the Commission’s major orders and regulatory decisions that have resulted in the construction of over $4 billion of needed new transmission and generation facilities in Wisconsin. He was elected to serve as lead representative by state regulators from 14 states and one Canadian province to represent them in matters before the Midwest System Operator, Inc. (MISO) and the Federal Energy Regulatory Commission (FERC). He also directed advocacy efforts on behalf of regulators and companies serving customers in the Upper Midwest before FERC and MISO during the critical months leading up to the start of a regional day-ahead energy market.

He has testified numerous times before Congress, FERC, the Nuclear Regulatory Commission and state legislatures on energy and telecommunications policy matters. He has served on the board of directors of the National Association of State Regulatory Commissioners (NARUC) and as chairperson of its Nuclear Waste Subcommittee. As a result of his extensive public affairs and public speaking experience, Garvin is a nationally recognized expert and commentator.

Garvin also served in Operation Iraqi Freedom as a staff judge advocate with the U.S. Army, 3rd Corps Support Command, 40th Corps Support Group, at Logistics Supply Area Anaconda in north-central Iraq from September 2005 to September 2006. In that capacity, Garvin served as senior prosecutor advising commanders on a wide variety of military justice matters across the Iraq theatre of operations.

Foley & Lardner LLP provides the full range of corporate legal counsel. Our attorneys understand today’s most complex business issues, including corporate governance, securities enforcement, litigation, mergers and acquisitions, intellectual property counseling and litigation,
outsourcing and information technology, labor and employment, and tax. The firm offers total solutions in the automotive, emerging technologies, energy, entertainment and media, financial services, food, golf and resort services, insurance, health care, life sciences, nanotechnology, and sports industries. The firm’s Web site can be found at www.foley.com.

MINNEAPOLIS, May 15, 2007 LAWFUEL – The Law Newswire — Lockridge Grindal Nauen P.L.L.P. announces that a class action has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Amgen, Inc. (“Amgen”) (Nasdaq:AMGN) publicly traded securities during the period May 4, 2005 through May 10, 2007 (the “Class Period).

If you are a member of the proposed Class, you may move the court to serve as a lead plaintiff for the Class on or before June 18, 2007. You do not need to be a lead plaintiff in order to share in any recovery that may be obtained.

The Complaint alleges that Amgen, a biotechnology company that makes and sells Epogen and Aranesp, drugs which encourage the creation of oxygen-carrying red blood cells, violated Federal Securities laws.
Specifically, it is alleged that Amgen marketed Aranesp and Epogen to doctors for off-label uses. As a result, Amgen sold several hundred million dollars worth of drugs each year for these off-label uses. In October 2006, a group of researchers stopped the progress of a clinical study of head and neck cancer patients treated with Aranesp because more deaths occurred in patients taking Aranesp than those taking a placebo. Amgen did not disclose those results to investors.

In February, 2007, a publication called The Cancer Letter, published an article about the results of the study and on March 9, 2007, the FDA mandated a warning regarding the off-label use of Aranesp and Epogen.
On May 8, 2007 in anticipation of an advisory panel meeting, the FDA issued a brief stating that in light of its findings, further modification to the labeling of ESAs may be appropriate. On May 10, 2007, an FDA outside panel of experts voted to expand warnings and require Amgen to conduct new studies to test the safety of ESAs. These events caused Amgen’s stock price to drop.

Plaintiff seeks to recover damages on behalf of the Class and is represented by Lockridge Grindal Nauen P.L.L.P.. If you have questions about the lawsuit or would like to discuss it with an attorney, please call or e-mail:

Karen H. Riebel, Esq. (khriebel@locklaw.com)
Lockridge Grindal Nauen P.L.L.P.
100 Washington Avenue South, Suite 2200
Minneapolis, MN 55401
(612) 339-6900